

June 29, 2026

Dr. Tracy Glynn
National Director of Operations and Projects
Canadian Health Coalition
488 Charlotte St. Apt. 1
Fredericton, NB E3B 1L8

Dear Dr. Glynn:

On behalf of the board at Canadian Blood Services, I would like to offer my sincere thanks for your presentation at our recent board meeting.

We have engaged the Canadian Health Coalition in past consultations on plasma supply and appreciated your participation. We are aware of the Coalition's position on commercial plasma collection and our agreement with Grifols.

It is important to emphasize that Canadian Blood Services' mandate is to meet the needs of Canadian patients by providing the products they need. Our responsibility is to ensure those products are safe and accessible. Our own operations, as well as those of Grifols, are in service of that mandate.

In terms of donor safety, all blood and plasma collections sites in Canada must be licensed to operate by Health Canada and are regulated under Health Canada's Blood Regulations, which includes operational requirements related to donor safety, mandatory reporting and compliance/inspection mechanisms. Health Canada identified some compliance deficiencies at some of the Grifols sites and appropriately imposed corrective requirements and continues its oversight. Grifols has stated publicly that it is taking the non-compliances seriously and is implementing corrective actions across its Canadian operations. We are confident these issues are being appropriately addressed, and Health Canada continues its oversight as the regulator.

You expressed concerns about the safety of products collected by commercial operators, compared to voluntary operators such as CBS. To be clear, there is no evidence that one system is safer than the other. Safety is determined by the strength of the regulatory framework, compliance with standards, and oversight, not by whether donors are compensated.

Paid plasma donation has been a growing reality in Canada for more than a decade. Through our agreement with Grifols, we have brought this pre-existing dynamic into the national blood system – ensuring it is managed in a way that prioritizes the needs of Canadian patients who rely on these life-saving therapies. This approach is consistent with the findings of the 2018 Health Canada expert panel, which underscored the importance of strengthening domestic plasma collection to support long-term access and found no evidence that regulated commercial plasma collection undermines the safety or sustainability of the broader blood system.

Canadian Blood Services' plan to strengthen Canada's immunoglobulin supply is deliberately balanced and safeguards the public system by combining significant expansion of CBS-collected plasma with a controlled agreement with Grifols to produce immunoglobulins exclusively for Canadian patients. Controls include defined collection limits, ongoing coordination, and continuous monitoring – to mitigate any potential impacts on CBS donor centres.

This is a pragmatic, made-in-Canada approach and one that ensures patients have a more secure and sustainable supply of the therapies they depend on.

Thank you, once again, for your presentation.

Sincerely,



Dr. Brian Postl, CM, OM, MD, FRCP(C), FCAHS
Chair, Board of Directors

c.c.: Dr. Graham Sher, Chief Executive Officer